News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
587,653 Results
Type
Article (47194)
Company Profile (122)
Press Release (540325)
Multimedia
Podcasts (142)
Webinars (19)
Section
Business (156048)
Career Advice (2427)
Deals (29202)
Drug Delivery (141)
Drug Development (71731)
Employer Resources (158)
FDA (16140)
Job Trends (12560)
News (280467)
Policy (30777)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2380)
Academic (1)
Accelerated approval (34)
Adcomms (36)
Allergies (134)
Alliances (37138)
ALS (166)
Alzheimer's disease (1728)
Antibody-drug conjugate (ADC) (320)
Approvals (16287)
Artificial intelligence (487)
Autoimmune disease (154)
Automation (32)
Bankruptcy (319)
Best Places to Work (9659)
BIOSECURE Act (23)
Biosimilars (191)
Biotechnology (71)
Bladder cancer (159)
Brain cancer (54)
Breast cancer (598)
Cancer (4596)
Cardiovascular disease (413)
Career advice (2051)
Career pathing (38)
CAR-T (258)
CDC (59)
Celiac Disease (1)
Cell therapy (722)
Cervical cancer (36)
Clinical research (61413)
Collaboration (1485)
Company closure (4)
Compensation (1137)
Complete response letters (72)
COVID-19 (2758)
CRISPR (86)
C-suite (768)
Cystic fibrosis (144)
Data (5867)
Decentralized trials (2)
Denatured (33)
Depression (145)
Diabetes (491)
Diagnostics (5758)
Digital health (34)
Diversity (7)
Diversity, equity & inclusion (43)
Drug discovery (215)
Drug pricing (221)
Drug shortages (33)
Duchenne muscular dystrophy (235)
Earnings (69802)
Editorial (65)
Employer branding (20)
Employer resources (141)
Events (96485)
Executive appointments (894)
FDA (19192)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (20)
Funding (1283)
Gene editing (193)
Generative AI (42)
Gene therapy (608)
GLP-1 (1075)
Government (4430)
Grass and pollen (8)
Guidances (379)
Healthcare (15662)
HIV (58)
Huntington's disease (49)
IgA nephropathy (84)
Immunology and inflammation (286)
Immuno-oncology (57)
Indications (94)
Infectious disease (3014)
Inflammatory bowel disease (185)
Inflation Reduction Act (14)
Influenza (106)
Intellectual property (231)
Interviews (454)
IPO (14699)
IRA (57)
Job creations (3214)
Job search strategy (1677)
JPM (66)
Kidney cancer (16)
Labor market (81)
Layoffs (617)
Leadership (39)
Legal (7230)
Liver cancer (91)
Longevity (12)
Lung cancer (614)
Lymphoma (359)
Machine learning (41)
Management (52)
Manufacturing (729)
MASH (166)
Medical device (11949)
Medtech (11993)
Mergers & acquisitions (15499)
Metabolic disorders (1323)
Multiple sclerosis (146)
NASH (22)
Neurodegenerative disease (328)
Neuropsychiatric disorders (96)
Neuroscience (2939)
Neurotech (1)
NextGen: Class of 2026 (5214)
Non-profit (3397)
Now hiring (31)
Obesity (657)
Opinion (281)
Ovarian cancer (152)
Pain (191)
Pancreatic cancer (218)
Parkinson's disease (281)
Partnered (26)
Patents (470)
Patient recruitment (446)
Peanut (54)
People (45671)
Pharmaceutical (35)
Pharmacy benefit managers (32)
Phase 1 (18279)
Phase 2 (26682)
Phase 3 (21677)
Pipeline (4884)
Policy (333)
Postmarket research (2379)
Preclinical (7564)
Press Release (37)
Prostate cancer (242)
Psychedelics (55)
Radiopharmaceuticals (254)
Rare diseases (873)
Real estate (4447)
Recruiting (64)
Regulatory (23571)
Reports (41)
Research institute (2155)
Resumes & cover letters (404)
Rett syndrome (27)
RNA editing (16)
RSV (73)
Schizophrenia (151)
Series A (217)
Series B (172)
Service/supplier (9)
Sickle cell disease (95)
Special edition (25)
Spinal muscular atrophy (143)
Sponsored (46)
Startups (2862)
State (1)
Stomach cancer (20)
Supply chain (104)
Tariffs (101)
The Weekly (108)
Vaccines (1087)
Venture capital (94)
Weight loss (464)
Women's health (72)
Worklife (22)
Date
Last 7 days (558)
Last 30 days (1949)
Last 365 days (28738)
2026 (2734)
2025 (29096)
2024 (32365)
2023 (36361)
2022 (46518)
2021 (50204)
2020 (47191)
2019 (38127)
2018 (28868)
2017 (28819)
2016 (27344)
2015 (30615)
2014 (24114)
2013 (19572)
2012 (21041)
2011 (21512)
2010 (19458)
Location
Africa (697)
Alabama (73)
Alaska (6)
Arizona (240)
Arkansas (10)
Asia (33661)
Australia (5873)
California (10565)
Canada (2615)
China (944)
Colorado (420)
Connecticut (458)
Delaware (304)
Europe (81842)
Florida (1569)
Georgia (324)
Hawaii (4)
Idaho (42)
Illinois (762)
India (51)
Indiana (443)
Iowa (22)
Japan (400)
Kansas (105)
Kentucky (25)
Louisiana (19)
Maine (74)
Maryland (1303)
Massachusetts (7619)
Michigan (274)
Minnesota (569)
Mississippi (5)
Missouri (119)
Montana (12)
Nebraska (22)
Nevada (112)
New Hampshire (62)
New Jersey (2848)
New Mexico (16)
New York (2748)
North Carolina (1370)
North Dakota (7)
Northern California (5213)
Ohio (281)
Oklahoma (15)
Oregon (34)
Pennsylvania (2038)
Puerto Rico (17)
Rhode Island (32)
South America (1057)
South Carolina (63)
South Dakota (1)
Southern California (4118)
Tennessee (153)
Texas (1569)
United States (36990)
Utah (286)
Virginia (245)
Washington D.C. (75)
Washington State (859)
West Virginia (4)
Wisconsin (108)
Wyoming (1)
587,653 Results for "recordati s p a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Moderna Teams With Recordati on Rare Disease mRNA Therapy for up to $160M
Moderna will continue to lead clinical development and manufacturing of the asset, while Recordati will handle commercialization of mRNA-3927, which is under development for the rare metabolic disorder propionic acidemia.
January 30, 2026
·
1 min read
·
Annalee Armstrong
Press Releases
RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA
January 30, 2026
·
5 min read
Press Releases
Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)
January 30, 2026
·
5 min read
Press Releases
Recordati Launches 12th Edition of Arrigo Recordati Prize to Support Research in Paediatric Oncology
October 22, 2025
·
3 min read
Press Releases
Recordati Rare Diseases to Share New Data at the American Society of Hematology (ASH) Meeting
November 3, 2025
·
6 min read
Press Releases
Recordati Rare Diseases Showcases Real-World Evidence Studies That Advance Understanding of Castleman Disease (CD) at the American Society of Hematology (ASH) Annual Meeting
December 8, 2025
·
12 min read
Press Releases
Recordati Rare Diseases Announces Real-World Data on Long-Term Safety of ENJAYMO® (sutimlimab-jome) in Cold Agglutinin Disease and Cold Agglutinin Syndrome (CAD/CAS) at American Society of Hematology (ASH) Annual Meeting
December 10, 2025
·
10 min read
Press Releases
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
January 29, 2026
·
2 min read
Press Releases
RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION
November 11, 2025
·
23 min read
Press Releases
RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE
June 25, 2025
·
4 min read
1 of 58,766
Next
